Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nat

The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humansFindings support further clinical development for prevention and treatment of dengue, which impacts millions of people today and is poised to threaten many more due to climate changeResearch builds on Johnson & Johnson’s endu...

Related Keywords

United States ,Bangladesh ,France ,Singapore ,Kigali ,W09 ,Rwanda ,Nepal ,America ,American ,Marnix Van Loock ,Ruxandra Draghia Akli ,Tesia Williams ,Trish Garrity ,Walter Reed Army Institute Of Research ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Global Health Discovery At ,Marseille University ,Department Of Infectious Diseases At Heidelberg University ,University Of Texas Medical Branch Health ,None Of The Janssen Pharmaceutical Companies ,Biomedical Primate Research Centre ,Global Public Health ,Sealy Institute For Vaccine Sciences ,Department Of Virology ,Exchange Commission ,Companies Of Johnson ,Ku Leuven Centre For Drug Design ,Ku Leuven Rega Institute ,Satellite Center ,Johnson ,Global Head ,Janssen Research ,Rega Institute ,Drug Design ,Infectious Diseases ,Heidelberg University ,Sealy Institute ,Vaccine Sciences ,Texas Medical Branch Health ,Des Virus ,Aix Marseille University ,Walter Reed Army Institute ,Latin America ,Emerging Pathogens ,Janssen Pharmaceutica ,Enduring Commitment ,Neglected Tropical Diseases ,Kigali Declaration ,American Society ,Tropical Medicine ,Global Health Discovery ,Pharmaceutical Companies ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,